172 related articles for article (PubMed ID: 34551034)
1. Durable response with lenvatinib and pembrolizumab combination therapy in a patient with pre-treated metastatic cholangiocarcinoma.
Dreikhausen L; Kusnik A; Schulte N; Eckardt M; Teufel A; Gaiser T; Ebert M; Zhan T
J Gastrointestin Liver Dis; 2021 Sep; 30(3):409-410. PubMed ID: 34551034
[No Abstract] [Full Text] [Related]
2. Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review.
Chen WX; Li GX; Hu ZN; Zhu P; Zhang BX; Ding ZY
Medicine (Baltimore); 2019 Nov; 98(45):e17832. PubMed ID: 31702638
[TBL] [Abstract][Full Text] [Related]
3. Significant response to pembrolizumab plus lenvatinib in Epstein-Barr-virus-associated intrahepatic cholangiocarcinoma: a case report.
Li L; Yu D; Yang J; Zhang F; Zhang D; Lin Z; Zhai M; Wang J; Zhang T; Zhao L
Cancer Biol Ther; 2024 Dec; 25(1):2338644. PubMed ID: 38650446
[TBL] [Abstract][Full Text] [Related]
4. Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma.
Huang Y; Du Z; Kan A; He M; Li H; Lai Z; Wen D; Huang L; Li Q; Xu L; Shi M
Front Immunol; 2024; 15():1260191. PubMed ID: 38384459
[TBL] [Abstract][Full Text] [Related]
5. Macro CD5L
Lu JC; Wu LL; Sun YN; Huang XY; Gao C; Guo XJ; Zeng HY; Qu XD; Chen Y; Wu D; Pei YZ; Meng XL; Zheng YM; Liang C; Zhang PF; Cai JB; Ding ZB; Yang GH; Ren N; Huang C; Wang XY; Gao Q; Sun QM; Shi YH; Qiu SJ; Ke AW; Shi GM; Zhou J; Sun YD; Fan J
Nat Commun; 2024 Jan; 15(1):621. PubMed ID: 38245530
[TBL] [Abstract][Full Text] [Related]
6. Durable response after discontinuation of pembrolizumab therapy for intrahepatic cholangiocarcinoma: a case report.
Eguchi S; Shinkawa H; Sato Y; Nakai K; Takemura S; Tanaka S; Amano R; Kimura K; Ohira G; Nishio K; Kinoshita M; Tauchi J; Miyazaki T; Ishihara A; Shirai D; Kubo S
Clin J Gastroenterol; 2021 Jun; 14(3):858-865. PubMed ID: 33811313
[TBL] [Abstract][Full Text] [Related]
7. Intrahepatic Cholangiocarcinoma with High Microsatellite Instability and Tumor Mutation Burden That Responded Significantly to Pembrolizumab but Perforated within a Short Period.
Yamazaki S; Kubota K; Shimizu A; Notake T; Umemura K; Kamachi A; Goto T; Tomida H; Yamashita N; Sato M; Kanno H; Soejima Y
Intern Med; 2024 Apr; 63(8):1105-1112. PubMed ID: 37779076
[TBL] [Abstract][Full Text] [Related]
8. Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma.
Law LY
J Clin Oncol; 2012 Sep; 30(27):e271-3. PubMed ID: 22851567
[No Abstract] [Full Text] [Related]
9. The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma.
Spahn S; Kleinhenz F; Shevchenko E; Stahl A; Rasen Y; Geisler C; Ruhm K; Klaumuenzer M; Kronenberger T; Laufer SA; Sundberg-Malek H; Bui KC; Horger M; Biskup S; Schulze-Osthoff K; Templin M; Malek NP; Poso A; Bitzer M
Nat Commun; 2024 Feb; 15(1):1287. PubMed ID: 38346946
[TBL] [Abstract][Full Text] [Related]
10. [A case of unresectable intrahepatic cholangiocarcinoma receiving sustainable pembrolizumab therapy].
Matsushita S; Ueo T; Minami R; Ozawa T; Matsumoto A; Kimura Y; Takeda Y; Okano A; Kusumi F; Ohana M
Nihon Shokakibyo Gakkai Zasshi; 2022; 119(4):360-367. PubMed ID: 35400689
[TBL] [Abstract][Full Text] [Related]
11. BINGO: targeted therapy for advanced biliary-tract cancer.
Valle JW
Lancet Oncol; 2014 Jul; 15(8):778-80. PubMed ID: 24852117
[No Abstract] [Full Text] [Related]
12. Effect and Mechanism of the Lenvatinib@H-MnO
Ning Z; Yang L; Yan X; Wang D; Hua Y; Shi W; Lin J; Meng Z
Curr Pharm Des; 2022; 28(9):743-750. PubMed ID: 35049427
[TBL] [Abstract][Full Text] [Related]
13. Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report.
Zhang Z; Zhang W; Wang H; Hu B; Wang Z; Lu S
Front Immunol; 2021; 12():744571. PubMed ID: 34603331
[TBL] [Abstract][Full Text] [Related]
14. Infigratinib in pretreated cholangiocarcinoma with FGFR2 fusions or rearrangements.
Neuzillet C
Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):773-775. PubMed ID: 34358483
[No Abstract] [Full Text] [Related]
15. Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study.
Luo X; Jia W; Huang Z; Li X; Xing B; Jiang X; Li J; Si A; Yang T; Gao C; Lau WY; Shen F
Oncotarget; 2017 Mar; 8(10):17246-17257. PubMed ID: 27783997
[TBL] [Abstract][Full Text] [Related]
16. [The progress of chemotherapy for intrahepatic cholangiocarcinoma].
Ioka T; Katayama K
Nihon Shokakibyo Gakkai Zasshi; 2012 Nov; 109(11):1895-901. PubMed ID: 23132033
[No Abstract] [Full Text] [Related]
17. Microsatellite Instability-high Intrahepatic Cholangiocarcinoma with Portal Vein Tumor Thrombosis Successfully Treated with Pembrolizumab.
Naganuma A; Sakuda T; Murakami T; Aihara K; Watanuki Y; Suzuki Y; Shibasaki E; Masuda T; Uehara S; Yasuoka H; Hoshino T; Kudo T; Ishihara H; Ogawa T; Kitamoto Y; Ogawa A
Intern Med; 2020 Sep; 59(18):2261-2267. PubMed ID: 32536644
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of pembrolizumab in microsatellite instability-high locally advanced cholangiocarcinoma: a case report.
Toshida K; Itoh S; Yoshizumi T; Shimagaki T; Wang H; Kurihara T; Toshima T; Nagao Y; Harada N; Oki E; Nakamura Y; Yoshino T; Mori M
Clin J Gastroenterol; 2021 Oct; 14(5):1459-1463. PubMed ID: 34085164
[TBL] [Abstract][Full Text] [Related]
19. [Systemic chemotherapy for cholangiocarcinoma].
Furuse J; Suzuki E; Hirokawa S; Kitamura H; Nagashima F
Nihon Shokakibyo Gakkai Zasshi; 2010 Jul; 107(7):1102-8. PubMed ID: 20616478
[No Abstract] [Full Text] [Related]
20. A case of toxic epidermal necrolysis associated with lenvatinib and sintilimab therapy for intrahepatic cholangiocarcinoma.
Gong Y; Mao J; Liu M; Gao J
J Int Med Res; 2023 May; 51(5):3000605231173556. PubMed ID: 37211771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
